Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity

Journal of Neuroimmunology

Volumn 104, Issue 2, 2000, Pages 101-108

  Currier, N L ^a   Sun, L Z Y ^a   Miller, S C ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Hemopoiesis; Melatonin; Monocytes; NK cells

Indexed keywords

MELATONIN;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CONTROLLED STUDY; HEMATOPOIESIS; IMMUNITY; IMMUNOMODULATION; MALE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE MARROW; CELL DIVISION; DIETARY SUPPLEMENTS; HEMATOPOIETIC STEM CELLS; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MELATONIN; MICE; MONOCYTES; SPLEEN;

EID: 0034192077     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00271-4     Document Type: Article

References (63)

1. Atre D., Blumenthal E.J. Melatonin: immune modulation of spleen cells in young, middle-aged and senescent mice. Mech. Ageing Dev. 103:(3):1998;255-268.
2. Beck B.N., Gillis S., Henney C.S. Display of the neutral glycolipoganglio-N-tetraosylceramide (Asialo-GM1) on cells of the natural killer and T cell lineages. Transplantation. 33:1982;118-122.
3. Biron C.A., Young H.A., Kasai M.T. Interleukin-2 induced proliferation of murine natural killer cells in vivo. J. Exp. Med. 171:1992;173-188.
4. Boranic M., Krizanac-Bengez L., Gabrilovac J., Marotti T., Breljak D. Enkephalins in hematopoiesis. Biomed. Pharmacother. 51:(1):1997;29-37.
5. Brown E.N., Choe Y., Shanahan T.L., Czeisler C.A. A mathematical model of diurnal variations in human plasma melatonin levels. Am. J. Physiol. 272:(Pt.1:3):1997;E506-E516.
6. Cavallo A., Ritschel W.A. Pharmacokinetics of melatonin in human sexual maturation. J. Clin. Endocrinol. Metab. 81:(5):1996;1882-1886.
7. Champney T.H., Prado J., Youngblood T., Appel K., McMurray D.N. Immune responsiveness of splenocytes after chronic daily melatonin administration in male Syrian hamsters. Immunol. Lett. 58:(2):1997;95-100.
8. Cho D., Wang J.L., Halloran P.J., Trinchieri G., Kim Y.B. Enhancement of porcine natural killer cell activity by recombinant human and murine IL-12. Cell. Immunol. 172:1996;29-34.
9. Christopher F.L., Dussault I., Miller S.C. Population dynamics of natural killer cells in the spleen and bone marrow of normal and leukemic mice during in vivo exposure to interleukin-2. Immunobiology. 284:1991;37-52.
10. Cutando A., Silvestre F.J. Melatonin: implications at the oral level. Bull. Groupement Int. Recherche Sci. Stomatol. Odontol. 38:(3-4):1995;81-86.
11. Demas G.E., Nelson R.J. Exogenous melatonin enhances cell-mediated, but not humoral, immune function in adult male deer mice (Peromyscus maniculatus). J. Biol. Rhythms. 13:(3):1998;245-252.
12. Dooley D.C., Law P., Alsop P. Granulocyte-monocyte progenitor cells from human peripheral blood: modulation of growth in vitro by T lymphocytes and monocytes. Int. J. Cell Cloning. 6:1988;45-59.
13. Dussault I., Miller S.C. Stimulation of natural killer cell numbers but not function in leukemic infant mice: a system primed in infancy allows survival in adulthood. Nat. Immun. 12:1993;66-78.
14. Dussault I., Miller S.C. Decline in natural killer cell-mediated immunosurveillance in aged mice - a consequence of reduced cell production and tumor binding capacity. Mech. Ageing Dev. 75:1994;115-129.
15. Dussault I., Miller S.C. Ineffectiveness of immunotherapy in aged leukemic mice. Gerontology. 41:1995;195-204.
16. Fraschini F., Demartini G., Esposti D., Scaglione F. Melatonin involvement in immunity and cancer. Biol. Signals Recept. 7:1998;61-72.
17. Garcia-Maurino S., Gonzalez-Haba M.G., Calvo J.R., Rafii-El-Idrissi M., Sanchez-Margalet V., Goberna R., Guerrero J.M. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 159:(2):1997;574-581.
18. Gonzalez-Haba M.G., Garcia-Maurino S., Calvo J.R., Goberna R., Guerrero J.M. High-affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J. 9:(13):1995;1331-1335.
19. Hermans M.H.A., Hartsuiker H., Opstelten D. An in situ study of B-lymphocytopoiesis in rat bone marrow. Topographical arrangement of terminal deoxynucleotidyl transferase-positive cells and pre-B cells. J. Immunol. 142:1989;67-73.
20. Hinuma S., Naruo K., Shiho O., Tsukamoto K. Characterization of murine non-specific killer cells induced in vivo by recombinant human interleukin-2. Immunology. 59:1986;251-259.
21. Inserra P., Zhang Z., Ardestani S.K., Araghi-Niknam M., Liang B., Jiang S., Shaw D., Molitor M., Elliott K., Watson R.R. Modulation of cytokine production by dehydropiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Proc. Soc. Exp. Biol. Med. 218:(1):1998;76-82.
22. Jacobsen K., Osmond D.G. Microenvironmental organization and stromal cell associations of B lymphocyte precursor cells in mouse bone marrow. Eur. J. Immunol. 20:1990;2395-2404.
23. Kasai M., Iwamori M., Nagai Y., Okumura K., Tata I. A glycolipid on the surface of mouse natural killer cells. Eur. J. Immunol. 10:1980;175-180.
24. Lesnikov V.A., Pierpaoli A. Pineal gross-transplantation (old-to-young and vice versa) as evidence for an endogenous 'aging clock'. Pierpaoli W., Regelson W. The Melatonin Miracle. 1996;177-284 Simon and Shuster, New York.
25. Lissoni P., Barni S., Ardizzoia A., Brivio F., Tancini G., Conti A., Maestroni G.J. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients. J. Biol. Regul. Homeost. Agents. 6:(4):1992;132-136.
26. Lissoni P., Barni S., Tancini G., Fossati V., Frigerio F. Pineal-opioid system interactions in the control of immunoinflammatory responses. Ann. NY Acad. Sci. 741:1994;191-196.
27. Lissoni P., Brivio F., Brivio O., Fumagalli L., Gramazio F., Rossi M., Emanuelli G., Alderi G., Lavorato F. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J. Biol. Regul. Homeost. Agents. 9:(1):1995;31-33.
28. Lissoni P., Brivio O., Barni S., Tancini G., Crippa D., Meregalli S. Adjuvant therapy with pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J. Pineal Res. 21:(4):1996;239-242.
29. Lissoni P., Paolorossi F., Ardizzoia A., Barni S., Chilelli M., Mancuso M., Tancini G., Conti A., Maestroni G.J. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal Res. 23:(1):1997;15-19.
30. Lissoni P., Rovelli F., Meregalli S., Fumagalli L., Musco F., Brivio F., Brivio O., Esposti G. Melatonin as a new possible anti-inflammatory agent. J. Biol. Regul. Homeost. Agents. 11:(4):1997;157-159.
31. Lissoni P., Tancini G., Barni S., Paolorossi F., Ardizzoia A., Conti A., Maestroni G. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer. 5:(2):1997;126-129.
32. Lissoni P., Rovelli F., Brivio F., Brivio O., Fumagalli L. Circadian secretions of Il-2, Il-12, Il-6 and Il-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans. Nat. Immun. 16:1998;1-5.
33. Maestroni G.J. Kappa-opioid receptors in marrow stroma mediate the hematopoietic effects of melatonin-induced opioid cytokines. Ann. NY Acad. Sci. 840:1998;411-419.
34. Maestroni G.J. Is hematopoiesis under the influence of neural and neuroendocrine mechanisms? Histol. Histopathol. 13:(1):1998;271-274.
35. Maestroni G.J. The photoperiod transducer melatonin and the immune-hematopoietic system. J. Photochem. Photobiol B. 43:(3):1998;186-192.
36. Maestroni G.J., Conti A. Melatonin and the immune-hemopoietic system therapeutic and adverse pharmacological correlates. Neuroimmunomodulation. 3:(6):1996;325-332.
37. Maestroni G.J., Conti A., Lissoni P. Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin-4. Cancer Res. 54:(17):1994;4740-4743.
38. Maestroni G.J., Conti A., Pierpaoli W. Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J. Neuroimmunol. 13:(1):1986;19-30.
39. Maestroni G.J., Covacci V., Conti A. Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res. 54:(9):1994;2429-2432.
40. Mallo C., Zaidan R., Galy G., Vermeulen E., Brun J., Chazot G., Claustrat B. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur. J. Clin. Pharmacol. 38:(3):1990;297-301.
41. Miller S.C., Christopher F.L., Dussault I. Population dynamics of natural killer cells and T lymphocytes in murine spleen and bone marrow during the development of erythroleukemia. Nat. Immun. 11:1992;78-91.
42. Miller S.C., Kaiserman M., Osmond D.G. Small lymphocyte production and lymphoid cell proliferation in mouse bone marrow. Experientia. 32:1978;129-130.
43. Miller S.C., Osmond D.G. Quantitative changes with age in bone marrow cell populations in C3H mice. Exp. Hematol. 2:1974;227-236.
44. Miller S.C., Osmond D.G. Lymphocyte populations in mouse bone marrow: Quantitative, kinetic studies in young, pubertal and adult C3H mice. Cell Tissue Kinet. 8:1975;97-110.
45. Mocchegiani E., Bulian D., Santarelli L., Tibaldi A., Muzzioli M., Lesnikov V., Pierpaoli W., Fabris N. The zinc pool is involved in the immune-reconstituting effect of melatonin in pinealectomized mice. J. Pharmacol. Exp. Ther. 277:(3):1996;1200-1208.
46. Naume B., Espevik T. Effects of IL-7 and IL-2 on highly purified CD56+ natural killer cells. J. Immunol. 147:1991;2208-2214.
47. Osmond D.G. B cell development in the bone marrow. Semin. Imunol. 2:1990;173-180.
48. Pang S.F., Tsand C.W., Hong G.X., Yip P.C., Tang P.L., Brown G.M. Fluctuations of blood melatonin concentrations with age: result of changes in pineal melatonin secretion, body growth and aging. J. Pineal Res. 8:(2):1990;179-192.
49. Pierpaoli W. The pineal gland: a circadian or a seasonal aging clock? Aging. 3:1991;99-101.
50. Pierpaoli W., Dall'Ara A., Pedrinis E., Regelson W. The pineal control of aging: The effects of melatonin and pineal grafting on the survival of older mice. Ann. New York Acad. Sci. 621:1991;291-313.
51. Pioli C., Carolea M.C., Nistico G., Doria G. Melatonin increases antigen presentation and amplifies specific and non-specific signals for T-cell proliferation. Int. J. Immunopharmacol. 15:(4):1993;463-468.
52. Poon A.M., Liu Z.M., Pang C.S., Brown G.M., Pang S.F. Evidence for a direct action of melatonin on the immune system. Biol. Sign. 3:(2):1994;107-117.
53. Provinciali M., Di Stefano G., Bulian D., Stronati S., Fabris N. Long-term melatonin supplementation does not recover the impairment of natural killer cell activity and lymphocyte proliferation in aging mice. Life Sci. 61:(9):1997;857-864.
54. Rafii-El-Idrissi M., Calvo J.R., Harmouch A., Garcia-Maurino S., Guerrero J.M. Specific binding of melatonin by purified cell nuclei from spleen and thymus of the rat. J. Neuroimmunol. 86:(2):1998;190-197.
55. Rogers N., van den Heuvel C., Dawson D. Effect of melatonin and corticosteroid on in vitro cellular immune function in humans. J. Pineal Res. 22:(2):1997;75-80.
56. Senik A., Gresser I., Maury C., Gidlund M., Orn A., Wigzell H. Enhancement of mouse NK cells by IFN. Trans. Proc. 11:1979;993-996.
57. Stout R.D., Schwarting G.A., Suttles J. Evidence that expression of Asialo-GM1 may be associated with cell activation. J. Immunol. 139:1987;2123-2129.
58. Whyte A.L., Miller S.C. Strain differences in natural killer cell mediated immunity among mice: A possible mechanism for the low natural killer cell activity of A/J mice. Immunobiology. 199:1998;23-28.
59. Wichmann, M.W., Zellweger, R., DeMaso, Ayala, A., Chaudry, I.H., 1996. Melatonin administration attenuates depressed immune functions following trauma-hemorrhage. J. Surg. Res. 63 (1), 256-262.
60. Williams J.G., Bernstein S., Prager M. Effect of melatonin on activated macrophage TNF, IL-6 and reactive oxygen intermediates. Shock. 9:(6):1998;406-411.
61. Wu C.Y., Warrier R.R., Caruajal D.M., Chua A.O., Minett L.J., Chizzonite R., Mongini P.K.A., Stern A.S., Gubler U., Presky D.H., Gately M.K. Biological function and distribution of human interleukin-12 receptor β-chain. Eur. J. Immunol. 26:1996;345-350.
62. Yeleswaram K., McLaughlin L.G., Knipe J.O., Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J. Pineal Res. 22:(1):1997;45-51.
63. Yellon S.M. Daily melatonin treatments regulate the circadian melatonin rhythm in the adult Djungarian hamster. J. Biol. Rhythms. 11:(1):1996;4-13.